Strategic collaborations ALLG pursues collaborative clinical trials and translational research initiatives, with recent partner activities including Mendus AB for AML maintenance studies. This points to opportunities to propose partnerships with CROs, biotechs, or pharma for trial design, site execution, or adjunct studies.

Registry leverage Housing the NBCR, the largest real-world AML data asset in Australia and NZ, positions ALLG as a high-value partner for data-driven trials, observational studies, and real-world evidence generation that attract sponsors seeking robust datasets.

Global outreach Active participation in major conferences such as ASH and Blood demonstrates ALLG’s engagement with global leaders. This suggests sales opportunities around sponsorships, speaking slots, or sponsor-led research collaborations at international events.

Leadership expansion Recent board appointments indicate ongoing governance and strategic growth. As the organization scales, there may be demand for strategic consulting, governance services, and expanded trial networks to support broader research programs.

Funding awareness Interest in research funding discussions evidenced by past Select Committee engagement implies potential for funding partnerships, grant-driven programs, and joint funding applications with industry partners to accelerate trial pipelines.